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ABSTRACT
OBJECTIVES: The objectives of this study were: (1) to determine prevalence of opioid
analgesics prescribing for non-ED dental related visits in the Mississippi Medicaid population,
(2) to assess predictors of receiving opioid analgesics following non-ED dental related events
among Mississippi Medicaid beneficiaries, and (3) to determine prevalence of opioid analgesic
prescribing for dental related emergency departments (ED) visits in the Mississippi Medicaid
population.
METHODS: A retrospective, cross-sectional, observational database analysis using Mississippi
Medicaid administrative claims data from January 1, 2015 to December 31, 2016. Beneficiaries
with dental related visits were included in this study. Descriptive statistics were utilized to assess
the prevalence of opioid prescribing for ED and non-ED dental visit events in the study period.
Logistic regression analyses were conducted to assess predictors of receiving an opioid
prescription following a non-ED dental related visit. Adjusted odds ratios, 95% confidence
intervals and p-values were calculated for the odds of receiving an opioid analgesic and the odds
of receiving an opioid analgesic with a morphine equivalent daily dose (MEDD) greater than the
median value of 25.
RESULTS: A total of 16,409 dental visit events were identified and 27% of dental visit events
were associated with an opioid prescription. Cleaning/preventive procedures had the lowest rate
of opioid prescribing (16%) while tooth extraction procedures had the highest rate of opioid
prescription (55%). Logistic regression showed that beneficiaries undergoing extraction
procedures had six times higher odds to be prescribed an opioid than those undergoing
cleaning/preventive procedures [OR=6.27, 95% CI: 4.64-8.46, P <0.0001]. Beneficiaries aged 18
or younger were less likely to receive an opioid in comparison to beneficiaries ages 19 to 45
years [OR=0.30, 95% CI: 0.27-0.33, P <0.0001]. Approximately 12% of opioid prescriptions for
dental diseases had dosages of 50 morphine equivalents/day or higher; 53% of these
prescriptions were written for more than a 3-day supply and 16% for more than a 7-day supply.
Approximately 42% of dental related ED visits events were associated with an opioid
prescription, and gum disease/periodontitis had the highest rate of opioid prescriptions for ED
visits at 48%.
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CONCLUSIONS: The findings of this study indicate that opioids are prescribed for many dental
procedures. This study has a broader policy implication for the state of Mississippi regarding
opioid abuse and misuse, drug utilization trend monitoring and curtailing opioid abuse by
broadening the lens to the field of dentistry.
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CHAPTER I
INTRODUCTION

Introduction
Opioids are a class of drugs used to treat moderate to severe pain. In the United States
(U.S.), some opioids are available by prescription, while other opioids, such as heroin, are
illegal to use. Some examples of prescription opioid analgesics include as oxycodone,
hydrocodone, codeine, and morphine (Compton & Volkow, 2006). Currently, there are 19 pure
prescription opioids (not including combinations) that are approved by the Food and Drug
Administration (FDA). Many of the current opioids on the market are combination products
containing one of the approved opioid medications. A list of all FDA approved opioid analgesic
medications can be found in Appendix A (FDA Drug Safety Communication, 2016).
The use of opioid medications for the treatment of various types of pain continues to
increase (Birnbaum et al., 2011; U.S. Department of Health and Human Services, 2011). The
hypnotic effect that opioids elicit have led to abuse and misuse when used for medical and nonmedical purposes. In 2010, it was estimated that 12.2 million people reported using pain
relievers non-medically for the first time within the past year (Ashrafioun, Edwards, Bohnert, &
Ilgen, 2014). With the increased use of opioids, there have also been increases in death due to
opioid overdose. The Centers for Disease Control and Prevention (CDC) reported that the
number of opioid-related poisoning deaths more than tripled from 1999 to 2003 (U.S.
Department of Health and Human Services, 2011). Drug overdose is the leading cause of
accidental death in the U.S with 47,055 lethal drug overdoses in 2014. Among these accidental
deaths, 18,893 overdose deaths were related to prescription pain relievers (Manchikanti, 2006).
Additionally, data from the National Center for Health Statistics reported that opioid analgesic
pain relievers were involved in more drug poisoning deaths than other specified drugs,
including heroin and cocaine (Rice, Kelman, & Miller, 1991). In the U.S., abuse of prescription
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pain medication continues to be a significant and growing problem and opioid use has taken a
center stage in this epidemic.
In addition to the mortality and addiction that occurs because of opioids, prescription
opioid abuse has a substantial economic cost to society. The estimated societal cost of
prescription opioid abuse in 2001 was $8.6 billion (Birnbaum et al., 2006). A few years later,
Birnbaum reassessed the societal cost of prescription opioid abuse in 2007 and estimated it to be
$55.7 billion (Birnbaum et al., 2011).

Dental Prescribing of Opioid Analgesics
Primary care providers account for approximately half of all prescribed opioid
prescriptions that are dispensed (Daubresse et al., 2013). Next to primary care physicians,
dentists are the second leading prescribers of immediate-release opioids (Substance Abuse and
Mental Health Services Administration, 2012), and have contributed significantly to the
prescription opioid volume in the U.S. by prescribing 12% of all immediate release opioid drugs
(Denisco et al., 2011). Opioid analgesics are generally used in dentistry for short-term pain
management associated with dental surgical procedures, and they are among the most
frequently prescribed drugs by dentists (Denisco et al., 2011; Moore & Hersh, 2013; Reece,
2007). Therefore, dentists also potentially play a very important role in opioid abuse and misuse
prevention (Moore, Nahouraii, Zovko, & Wisniewski, 2006b; Oakley, O’Donnell, Moore, &
Martin, 2011).
In recent times, physician and dental prescription practices have been under the public
lens regarding opioid misuse, abuse, and diversion by patients in part due to their prescribing
habits. Dental pain, like other forms of pain, is very subjective regarding severity measurement
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and most pain scales are unreliable. Hence, in practice, dentists rely on patient complaint and
symptoms experienced to determine the necessity to prescribe pain medications. Additionally,
dentists are not aware of a patient’s history of substance abuse unless voluntarily reported by
the patient (McCauley et al., 2016).
Dentists are also usually limited in exposure to drug and opioid addiction training and
reporting strategies, such as prescription drug monitoring programs (PDMPs) (Ashrafioun et al.,
2014; McCauley et al., 2016). Despite this, a limited number of studies regarding dental opioid
prescribing practices and the frequency of multiple concurrent opioid prescriptions among
dental patients have been conducted (Deyo et al., 2015; Hersh et al., 2011; Oakley et al., 2011).
Similarly, very little is known about the extent to which dental patients report diverting
prescription opioids intended for acute dental pain for purposes not intended by the dental
prescriber (Ilgen et al., 2012).
Dental clinics that provide affordable dental care, such as university dental training
clinics, have been reported to commonly treat patients with alcohol-related problems and/or
illicit drug use (Moore et al., 2006b). Another area of consideration when prescribing analgesics
by dentists and physicians is determining the patients for whom opioid analgesics are necessary
and appropriate, and if so, determining the dose and quantity that should be appropriately
prescribed. This is partly due to the prevalence of substance and alcohol abuse that can be
encountered within the dental patient population, and also because substance abusers frequently
obtain prescription drugs from friends and family for non-medical purposes (Johnson, Hearn, &
Barker, 2008).
Regarding emergency department (ED) visits, the number of ED visits for dental pain in
the U.S. increased from 1.1 million in 2000 to 2.1 million in 2010 (Wall et al., 2013). Many
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more patients with dental pain seek care at the ED and could be prescribed an opioid analgesic
without an understanding of their substance abuse history which poses unique problems.
(Mendonca et al., 2010; Reece, 2007).
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CHAPTER II
LITERATURE REVIEW
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Pain and Opioids
Pain is one of the most common diagnoses in primary care facilities (Volkow &
McLellan, 2011), and is presented as a complaint by nearly two-thirds of emergency department
patients treated in the United States (U.S.) (Cordell et al., 2002). Opioid analgesics have
become commonly used for the treatment for moderate to severe pain and have vastly improved
the quality of life for many. Nonetheless, its addictive properties have also resulted in potential
for abuse and misuse (Bhamb et al., 2006; Gudin, 2012; Victor, Alvarez, & Gould, 2009). Over
time, the number of prescribed opioid analgesics, such as fentanyl, oxycodone, hydrocodone,
and methadone, has increased. A report by Levy et al. (2015) on opioid prescription indicates
that opioid prescription volume increased by 11.4% between 2007 and 2012 (Levy, Paulozzi,
Mack, & Jones, 2015) and deaths due to the abuse and misuse of such analgesics has nearly
doubled (Johnston, 2010).
Opioid analgesics are typically prescribed for acute and chronic pain by primary care
physicians, emergency room physicians, and dentists. In the U.S., the number of opioid
prescriptions filled by pharmacies increased by 27% (from 174 million to 238 million) between
2000 and 2011 (Manchikanti et al., 2012). As the use of opioids analgesics for pain
management has increased, so has the incidence of opioid abuse and misuse (Manchikanti et al.,
2012). As a result of this increase, opioid analgesics have come under public scrutiny from
policymakers, patient advocacy groups and clinicians (Okunseri, Okunseri, Xiang, Thorpe, &
Szabo, 2014).
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Opioid Abuse and Misuse
Pain medications containing hydrocodone and oxycodone have been identified as the
most common choice among prescription opioid abusers and misusers. A 2012 National Survey
on Drug Use and Health (NSDUH) study estimated that approximately 4.5 million people, who
12 years or older reported nonmedical use of pain relievers in the past month (Substance Abuse
and Mental Health Services Administration, 2012).
Opioid abuse and consequently overdose have been increasing steadily in the U.S. for
over two decades. Accordingly, rates of prescription opioid poisoning and overdose have risen
threefold between 1999 and 2008, and have outpaced popular illicit drugs, such as cocaine and
heroin (Paulozzi, Jones, & Mack, 2011). Legitimate prescriptions, and the subsequent misuse
(intentional and unintentional as well as diversions) of opioid prescriptions, constitute a major
source of the current epidemic of opioid abuse (Inciardi et al., 2009; Shei et al., 2015; VoepelLewis, Wagner, & Tait, 2015; Wisniewski, Purdy, & Blondell, 2008). Deaths as a result of
opioid overdose have increased fourfold between 1990 and 2010, and it is estimated that about
100 people die each day from an opioid related overdose (CDC, 2013; Coben et al., 2010).
Katz et al. (2007) defines drug misuse as the “use of a medication other than as directed
or as indicated, whether willful or unintentional, and whether harm results or not”, and drug
abuse as “any use of an illegal drug or the intentional self-administration of a medication for a
non-medical purpose”. Consequences of opioid misuse include opioids poisoning and overdose,
and this can occur among individuals who misuse a duly prescribed opioid by taking the
medication differently from how it was prescribed. It is important to note that there are other
ways in which patients abuse and misuse medications. For example, “doctor shopping” is a
phenomenon in which patients visit multiple physicians to obtain opioids in amounts that are
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not intended for medical purposes (Cepeda, Fife, Chow, Mastrogiovanni, & Henderson, 2013).
Doctor shopping also poses other problems because of the potential for illegitimate drug misuse
and possible distribution to others without a prescription (Rigg, Kurtz, & Surratt, 2012). A prior
study showed that about 5 to 23% of all prescription opioids dispensed were used for nonmedical purposes (Savage, Covington, Gilson, Gourlay, Heit, & Hunt, 2004) with immediaterelease (IR) opioids such as hydrocodone and oxycodone being the most commonly abused
(Substance Abuse and Mental Health Services Administration, 2012).
The major sources of obtaining prescription drugs that are used for non-medical
purposes are family members, friends and in some cases through prescriptions (Substance
Abuse and Mental Health Services Administration, 2012). Research by the National Survey on
Drug Use and Health (NSDUH ) survey reported that in 2008/2009, among people over 12
years of age who had used pain relievers non-medically in the prior year, 70% obtained these
drugs from friends or family while 4.8% obtained their pain relievers from drug dealers
(Substance Abuse and Mental Health Services Administration, 2012). A 2008 study in the state
of Utah reported that 72% of respondents who were prescribed an opioid pain medication had
some left over, and 71% of those with leftover medication kept it for future use (CDC, 2010).
Additionally, unintentional diversion, in which medication is obtained from family and/or
friends, also has been consistently reported as a major source of opioids among adolescent
abusers (McCabe, West, & Boyd, 2013a).
Adolescents, particularly, are at risk for opioid overdose. In 2009, the National Institutes
of Health’s National Institute on Drug Abuse convened, in Rockville, MD, to examine how
opioid prescribing pattern in dental settings might contribute to opioid abuse among adolescent
patients. This meeting indicated the need for a greater understanding of opioid prescribing
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practices in dental offices, including the quantity typically prescribed by dentists as well as the
quantity that is needed for adequate post procedural pain management in order to prevent
addiction, misuse and abuse (Denisco et al., 2011). To highlight the concern regarding the
proliferation of hydrocodone and oxycodone products, the Drug Enforcement Agency (DEA)
recently rescheduled hydrocodone products as Schedule II controlled substances (Drug
Enforcement Administration, 2014).

Cost Associated with Opioid Abuse and Misuse
Hansen et al. (2011) estimated total costs to be $53.4 billion (2006) for nonmedical use
of prescription opioids, of which $42 billion (79%) was attributable to lost productivity, $8.2
billion (15%) to criminal justice costs, $2.2 billion (4%) to drug abuse treatment, and $944
million (2%) to medical complications. Workplace costs related to absenteeism, lost wages and
disability accounted for $25.6 billion (46%), health care costs accounted for $25.0 billion
(45%), and criminal justice costs accounted for $5.1 billion (9%) (Birnbaum et al., 2011).
McAdam-Marx et al. (2010) evaluated the average yearly cost after an index opioid
abuse diagnosis among Medicaid beneficiaries and reported that total costs were significantly
higher for the abuse/dependence patients ($14,537) than for patients who were not taking
opioids ($8,663) (P < .001). When controlling for baseline characteristics, adjusted costs
continued to be higher for abuse/dependence patients ($23,556 versus $8,436; P < .001)
(McAdam-Marx et al., 2010).
Inocencio et al. (2013) reported the average direct cost per poisoning or overdose event
was estimated to be $4,006. However, the average direct costs per poisoning were lower for
heroin when compared to opioids ($3,198 vs. $4,255). The mean ED treatment cost for all
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opioids was estimated to be $1,832. Total estimated direct annual costs to the U.S. were
estimated to be $2.2 billion. Prescription opioid poisoning accounted for 80% of all direct
medical costs. Specifically, total direct costs were highest for oxycodone ($616 million),
hydrocodone ($428 million), methadone ($289 million) and unspecified opioids ($350 million)
(Inocencio et al., 2013).

Opioid Overdose Deaths
The United States is currently going through an epidemic due to drug overdose deaths.
Since 2000, there has been a 137% increase in the number of deaths from drug overdoses,
including a 200% increase in the rate of overdose deaths involving opioids (i.e. opioid pain
relievers and heroin) (Rudd et al., 2016). Unintentional poisoning in general currently
represents the leading cause of injury related death in the U.S. for adults ages 25–64 years
(Murphy et al., 2013; U.S. Department of Health and Human Services, 2011).
The CDC analyzed mortality data to investigate trends of drug overdose deaths, and the
types of opioids associated with overdose deaths. In 2014, a total of 47,055 drug overdose
deaths occurred in the U.S., representing an increase of 6.5% in one year, from 13.8 per 100,000
persons in 2013 to 14.7 per 100,000 persons in 2014 and increased to 16.3 per 100,000 persons
in 2015 (Rudd et al., 2016).
Miller et al. (2015) reported a correlation between the type of opioid and potential for
overdose. After adjustment for age, sex, and opioid dose, patients who received long-acting
opioids were two times more likely to overdose as compared to patients who received shortacting opioids. (Hazard Ratio, 2.33; 95% CI: 1.26-4.32). The risk of overdose associated with
long-acting opioids was particularly significant during the first two weeks after commencement
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of treatment (Hazard Ratio, 5.25; 95% CI: 1.88-14.72) (Miller et al., 2015). Additionally, the
rate of drug overdose deaths increased significantly for males and females, in people aged 25–
44 years and ≥55 years, in non-Hispanic whites and non-Hispanic blacks. Geographically, in the
South, Northeast and Midwestern regions of the US, rates of overdose deaths caused by opioids
also increased significantly, from 7.9 per 100,000 in 2013 to 9.0 per 100,000 in 2014, a 14%
increase in one year (Rudd et al., 2016).

Prevalence of Opioid Prescribing Among Dentists
Data from IMS Health also shows that dentists prescribe about 6.4% of all opioids
dispensed in the US; which is equivalent to 18.5 million opioid prescriptions in 2012 (Levy et
al., 2015). Denisco et al. (2011) surveyed oral and maxillofacial surgeons and reported that they
performed an average of 53 (range 45 to 69) third-molar extractions per month. Extrapolating
this information to all 5,542 practicing oral and maxillofacial surgeons in the U.S. at the time,
an estimate of 3.5 million third-molar extractions were conducted annually among oral and
maxillofacial surgeons, excluding general dentists (Moore, Nahouraii, Zovko, & Wisniewski,
2006a). Hence, up to 3.5 million people may be exposed to the possibility of obtaining opioid
analgesics through dental procedures (Denisco et al., 2011).
In a statewide survey conducted in West Virginia in 2010, practicing dentists in the state
were asked about their prescribing patterns and experience with drug and substance abuse,
misuse and diversion. Among the dentists who did not prescribe opioids, the most commonly
prescribed pain relievers were non-steroidal anti-inflammatory drugs (NSAIDs) (64%),
followed by acetaminophen (28%). Among those who prescribed opioids, the most commonly
prescribed opioid was hydrocodone combined with acetaminophen (73%) (Denisco et al.,
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2011). There was considerable variation regarding the amount of opioids prescribed following a
third molar extraction procedure. However, the duration of use was typically between two to
five days in about 86% of the cases. More importantly in the fight against drug diversion, about
41% of dentists who prescribed an opioid expected patients to have some medication leftover
(Denisco et al., 2011).
Prior research has focused on opioid prescribing by dentists after molar extractions,
reporting that most (85.0%) dentists prescribed an opioid, most often hydrocodone with
acetaminophen, with instructions to take for pain as needed (Haegerich, Paulozzi, Manns, &
Jones, 2014). A pilot study by Ilgen, Edwards and Kleinberg (2012) on opioid prescriptions by
dentists provided an estimate of the prevalence of nonmedical use of opioids and diversion
among dental patients receiving care at an outpatient dental clinic. The study reported that
37.9% of dental patients reported some form of nonmedical use of prescription opioids and
6.5% reported diverting their initial dental medication; which indicates that dental patients may
be at a risk of opioid medication abuse and misuse (Ilgen et al., 2012).
Various government public health agencies such as the Office of National Drug Control
Policy, the Department of Health and Human Services, and the National Institute on Drug
Abuse have identified prescribers as critical intervention points in the fight against the
prescription drug abuse epidemic (U.S. Department of Health and Human Services, 2015;
Volkow, 2014). A study in a national health care plan with about 2 million beneficiaries
reported that providers who were specialists were more likely to prescribe extended release
opioids for pain that lasted at least 60 days (Victor et al., 2009). In a large national sample with
121 million patients including prescription data from more than half of the retail pharmacies in
the U.S, it was reported that primary care physicians (i.e., general practitioners, family medicine
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practitioners and internists) prescribed more opioids (28.8%) to prescribe opioids, compared to
dentists (8.0%) and orthopedic surgeons (7.7%) (Volkow, McLellan, Cotto, Karithanom, &
Weiss, 2011).
Rigoni reported, in 2003, that dentists prescribe 12% of immediate-release opioids in the
U.S, preceded only by family physicians, who prescribe 15% of immediate-release opioids
(Rigoni, 2003). Due to information showing that immediate-release opioids constitute the
majority of nonmedical use of opioids, dentists have some contribution to this phenomenon
(Denisco et al., 2011).
Dentists have reported prescribing opioid medication for the management of pain for
procedures such as root canal, implants and tooth extraction. Prior research also consistently
shows that most opioid prescriptions prescribed by dentists were for immediate-release
formulations, specifically various hydrocodone combinations (Weiland et al., 2015).
A pilot study by Ilgen et al. (2012) on opioid prescriptions by dentists provided an initial
estimate of the prevalence of nonmedical use of opioids and diversion among dental patients
receiving care at an outpatient dental clinic. The study showed that 37.9% reported some form
of nonmedical use of prescription opioids and 6.5% of respondents reported diverting their
initial dental medication; which indicates that dental patients may be at an increased risk of
opioid medication abuse and misuse (Ilgen et al., 2012).
Dentists prescribe about 1 of every 10 immediate-release opioids dispensed, and opioid
prescriptions account for a high proportion of all dental prescriptions (Denisco et al., 2011;
Ringwalt et al., 2014). Prior literature suggests that (a) dental patients are potentially vulnerable
to personal abuse and misuse of opioid medication (Ashrafioun et al., 2014 ), (b) dental patients
regularly have unused leftover opioid medication that constitutes a significant proportion of
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nonmedical use (McCabe, West, & Boyd, 2013b), and (c) access to dental care at a community
level is associated with higher rates of opioid abuse because there is an increased availability of
prescription opioids (Wright et al., 2014). However, dentists’ prescribing patterns may be
impacted by increased regulation and prescribing requirements associated with the DEA’s
decision to reschedule hydrocodone, which could potentially lead to consideration of
alternatives for the management of post-procedural pain (Golembiewski, 2015; Curro, 2013)
Dentists regularly encounter patients with addiction which is not just limited to opioid
addiction, nevertheless many dentists say they have limited exposure to information regarding
addiction treatment which includes but not limited to screening, interventional and referral
programs to assist addicts (Ilgen et al., 2012; McNeely et al., 2013). Prescription opioid
medications can constitute a risk to those affected by opioid dependency because these
prescription while written legitimately for pain control, can be sold on the street, stolen by
family members or taken in excess quantities not recommended by the prescriber (CDC, 2013).
Adverse effects of opioid misuse can include the development of more chronic and
severe substance use, overdose deaths and other unintentional fatalities (Bohnert et al., 2011;
Meyer, Patel, Rattana, Quock, & Mody, 2014; Yokell et al., 2014). Hasegawa et al. (2014)
reported that ED visits related to opioid overdose have quadrupled between 1993 to 2010
increasing from 19 to 63 per 100,000 ED visits (+235%; Ptrend < 0.001). Imtiaz et al., (2014)
demonstrated that there have been corresponding increases in admission rates, morbidity, and
mortality related to opioid use by showing that consumption levels of prescription opioids were
very strongly correlated with morbidity and mortality measures per 10,000 people (r =0.95) and
opioid overdose deaths per 100,000 people (r =0.99) (Imtiaz, Shield, Fischer, & Rehm, 2014).

15

Despite increased attention to physician prescribing practices, as well as the role of the
dental prescriber in promoting and preventing opioid misuse, abuse, and diversion, limited
representative data exists regarding dental opioid prescribing practices and the frequency of
multiple concurrent opioid prescriptions among dental patients (Denisco et al., 2011; Haegerich
et al., 2014; Nuckols et al., 2014).
Prescription opioid misuse and abuse has increased over the past decade and can been
attributed in large part to higher rates of opioid prescribing. Various initiatives across the nation
such as prescription drug monitoring programs PDMPs have sought to prevent and reverse
opioid abuse and consequently overdose death through education and increasing access to
naloxone (Wheeler, Davidson, Jones, & Irwin, 2012). Despite the concern regarding the misuse
and abuse of prescription opioids, physicians continue to be able to prescribe them with a
balance to the risk and also ensuring that the patients receive the best possible care for their pain
(Inocencio et al., 2013).
Also, literature suggests that dentists do not routinely use prescription drug monitoring
programs (PDMP) when they prescribe opioid medications (Herman, 2011). PDMPs are
databases collected from pharmacies on dispensed controlled substances such as opioids and in
some cases benzodiazepines and makes them available to physicians, dentists and pharmacists
with the aim of identifying patients who are at risk for, abuse or misuse (Hansen, 2015; Jena,
Goldman, Weaver, & Karaca-Mandic, 2014; Paulozzi, 2012).
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Prescription Drug Monitoring Programs
Prescription Drug Monitoring Programs (PDMPs) are state run electronic databases that
collect data from pharmacies on dispensed controlled substances and make it available to
authorized prescribers and pharmacists in order to monitor and identify patients that are at a
high risk of opioid abuse (Hansen, 2015). Information from PDMPs are valuable in the
identification of patients with concurrent opioid medications which is an indicator of risk for
opioid abuse, misuse and overdose (Green et al., 2013; Jena et al., 2014; Paulozzi, 2012).
By October 2012, all 50 states in the U.S. had enacted laws establishing a prescription
drug monitoring program, with 42 states having operational programs for monitoring in place
(Alliance of States with Prescription Monitoring Programs, 2012). PDMPs allow for active
monitoring of prescribing and dispensing records for selected drugs of abuse and are intended to
aid providers, including dentists, as well as law enforcement to control prescription drug abuse,
misuse and controlled substance use history. PDMP data is used differently depending on the
state, nonetheless in most states, information is provided to pharmacy and other health care
professionals and, in some cases can be provided to law enforcement (Inocencio et al., 2013).
Some states have enacted legislation that mandates the use of PDMPs prior to prescribing
opioid substances (Rasubala, Pernapati, Velasquez, Burk, & Ren, 2015). Dentists also reported
never using the PDMP because they were not aware it existed or did not know how to access it
(Ilgen et al., 2012, McNeely et al., 2013). However, dentists reporting PDMP use found it at
least somewhat helpful and PDMP use contributed to prescribing fewer opioid doses
(McCauley, Leite, Melvin, Fillingim, & Brady, 2016).
Evidence from research suggests that prescribers may have incorrect perceptions of their
patients’ risk for drug abuse or misuse (Bartley et al., 2015). Hence, regular use of PDMP data
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to inform and improve prescription decisions is highly recommended (Brady et al., 2014;
Haegerich et al., 2014; Haffajee, Jena, & Weiner, 2015; Rasubala et al., 2015). Training
prescribers like dentists on PDMP use, patient education regarding addiction, is a key national
strategy to prevent opioid abuse, misuse and diversion (US Department of Health and Human
Services, 2015). Proper training in identification of drug misuse was one major reason why
dentists’ choose to use PDMP’s prior to prescribing, and an overwhelming majority of dentists
have an interest in continuing education regarding opioid abuse and misuse as most current
dentists have no training in strategies to identify and prevent opioid misuse in their practice
(McCauley et al., 2016).Various reasons have been identified as possible barriers to the
adoption of PDMPs and these include a general lack of awareness, barriers to accessibility,
quality and interpretability of data, uncertainty regarding how to respond in instances of
suspected misuse or abuse, litigation fears and privacy concerns (Deyo et al., 2015; Griggs,
Weiner, & Feldman, 2015; Islam & McRae, 2014; Rutkow, Turner, Lucas, Hwang, &
Alexander, 2015).
Research on potential factors associated with physician opioid prescribing practices has
been limited and inconclusive. While some investigations have linked such prescriptions to pain
scores (Fanciullo, Hanscom, Seville, Ball, & Rose, 2001), some others have not (Breckenridge
& Clark, 2003; Turk & Okifuji, 1997). Some clinicians suggest instead that patients’ painrelated behaviors, particularly their distress and disability levels, might be more associated with
the prescribing practices of providers than pain scores. The role of practitioner specialty as a
factor in the prescribing of opioid medication remains conflicting due to the complex nature of
drug abuse (Heins et al., 2006; Heins, Homel, Safdar, & Todd, 2010). The lack of substantiated
evidence regarding providers and prescription of opioids this has led researchers to conclude
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that opioid prescribing habits are largely idiosyncratic and based largely on providers’ beliefs
regarding their appropriateness (Tamayo-Sarver, Dawson, Cydulka, Wigton, & Baker, 2004).
This necessitates further research into the role of practitioners as a factor in the debate on opioid
abuse.

Emergency Department Use for Dental Problems
Emergency departments (EDs) are a very crucial point of entry into the health care
system, particularly for people who have difficulty accessing routine preventive health care
services. This problem is more pronounced for dental related problems because an estimated
44% of Americans lack dental insurance. Due to this, many experience difficulties in access to
dental services (CDC, 1997).
According to the National Hospital Ambulatory Medical Care Survey (NHAMCS), the
number of dental ED visits in the U.S. increased from 1.1 million in 2000 to 2.1 million in 2010,
representing an increase in the rate and signifies an increasing reliance on emergency services for
dental related procedures (Wall et al., 2013). In 2006, there were 120,033,750 hospital-based
emergency department visits across the United States and among these, a total of 330,757 visits
to hospital ED visits were primarily attributed to dental caries alone. Children accounted for
24,982 visits, whereas adults accounted for 305,775 visits. Fifty-two percent of all visits
occurred among females (Nalliah et al, 2010).
According to Okunseri et al. (2015), 50.3% of patients with a non-traumatic dental
related visit to the emergency department received an opioid, and the rates for each specific
prescribed opioid examined (hydrocodone, oxycodone, and codeine) were 31.6%, 12.3%, 4.1%,
respectively (Okunseri et al., 2015). The proportion of Medicaid enrollees with non-traumatic
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dental conditions was 29.8% and represented the highest rate compared to other forms of
insurance (Okunseri et al., 2015).
Income plays a huge role in predicting ED visits with close to 38% of all visits by both
children and adults occurring among individuals residing in lower income areas. This highlights
income based disparities in dental healthcare access and emergency room utilization in the
United States (Nalliah et al., 2010). A dental ED visit study showed that uninsured individuals
account for about approximately 45% of all emergency room dental related visits and close to
20% of all visits by children occurred among children who were uninsured. Medicaid was also
the most common payer for all visits by children, accounting as the payer for nearly 53% of all
visits (Nalliah et al., 2010).
A dental health study in New York found that 67% of oral health related visits to
emergency departments by children who were younger than 6 years of age were attributable to
dental caries (Wadhawan et al., 2003). Wilson et al. (1997) reported that 73% of children
presenting for dental emergencies in an ED had a primary diagnosis of dental caries.
Additionally, Graham et al. (1999) examined the incidence of pediatric emergency room visits
for non-traumatic, preventable dental disease, and reported that 48% of cases had a primary
diagnosis of caries. Evidently, dental caries is an important personal and public health issue
among children. In general, patients who present at an ED with a dental condition would be
better served in a dental office setting due to the availability of definitive care and the likelihood
of continuity of care as well as the ability to have a one on one encounter with the dental
provider (Okunseri et al., 2014).
Emergency departments are an important point of care for dental-related problems,
particularly for people who are uninsured. Emergency departments and their providers should be
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prepared and equipped to diagnose, provide basic treatment, and, if possible, ensure that followup care for dental problems within dental offices should be carried out (Lewis, Lynch, Johnston,
2003). Emergency departments may even face greater numbers of patients with dental
complaints if the uninsured population increases and if the current barriers (such as income and
insurance coverage) to accessing dental care are not addressed. There is a need for dental training
for emergency care providers, as well as for improving dental care during and after ED visits,
should be assessed (Lewis, Lynch, Johnston, 2003).

Study Significance
This study examined the patient demographic characteristics as well as disease factors
that potentially influence dental patients receiving opioid prescriptions from dentists. Patient
level information gives policy makers an understanding of the patient population exposed to
opioids through the dentist. Additionally, examining emergency department visits with dental
diagnoses can help improve understanding of the burden of emergency department visits for
dental purposes, which can inform policy and policy regarding the potential for opioid abuse
through opioids administered through the emergency department in the Mississippi Medicaid
population.
There is limited literature on the prescribing patterns of dental providers and even less so
on predictors of dental opioid prescribing. This study attempts to assess dental opioid
prescriptions by understanding the dentist who prescribes and the patient who obtains these
prescriptions. Prior research has examined the prevalence of emergency department visits due to
dental caries in children. However, this study presents a view of emergency department visits for
dental problems and opioid prescriptions associated with them.
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METHODOLOGY
Study Objectives
The objectives of this study were:
1) To determine prevalence of opioid analgesics prescribing for non-ED dental related
visits in the Mississippi Medicaid population.
2) To assess predictors of receiving opioid analgesics following non-ED dental related
events among Mississippi Medicaid beneficiaries.
3) To determine prevalence of opioid analgesic prescribing for dental related emergency
departments (ED) visits in the Mississippi Medicaid population.
Data Source
The Mississippi Division of Medicaid is a state branch of the United States program that
was designed to provide health coverage for indigent families and individuals. Medicaid is a
means tested program which is jointly funded by the Federal government and state government,
but it is administered by the individual states.
Mississippi Division of Medicaid administrative claims data files were used for this
study. The data files include information about enrollment and eligibility; inpatient, outpatient
and emergency department services; prescription drug claims; costs; dates of service; and
demographics for each beneficiary.
Mississippi Medicaid Administrative Claims Database
The Medicaid administrative claims make up the database. To protect patient privacy,
all the beneficiary files were de-identified. These files include: enrollment, inpatient,
outpatient, medical, pharmacy, provider information.
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The Medicaid beneficiary master file contains enrollment information for all Medicaid
beneficiaries. This file contains patient data such as date of birth, gender, race, basis of
eligibility, dual eligibility status, insurance type, monthly enrollment status, and county of
residence.
The inpatient claims file is a claim level file that contains information of complete
hospital stay records for beneficiaries who used inpatient services including diagnoses (e.g.,
ICD-CM), Current Procedural Terminology (CPT) codes, ED visits, discharge status, length of
stay, and payment amount.
The medical claims files are claim level files that contain information related to officebased visits, diagnosis (e.g., ICD-CM), procedure codes (e.g., CPT) date of service, provider
type, and amount paid. Claims in medical file are generated from physician’s private practice.
The National Provider Identifier (NPI) is a unique 10-digit identification number for
health care providers, including both organizations and individuals. This file contains provider
information including provider type, description, state of practice, county of practice.
The outpatient claims file is also claim level file that provides information regarding
hospital-outpatient visits, diagnosis codes (e.g., ICD-CM), procedure code (e.g., CPT), date of
service, and billing information. Claims in the outpatient file are generated in hospital settings.
The prescription claims file is a claim level file that contains information related to filled
prescriptions. These claims include: the drug name of the filled medication, dispense date,
quantity supplied, number of refills, number of days supplied, amount paid, and National Drug
Code (NDC).
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Ethical Considerations
Application for human subjects research was submitted and approved by the
Institutional Review Board at The University of Mississippi, University, MS.

Study Design
This study is a retrospective, cross-sectional, observational database analysis using
Mississippi Medicaid administrative claims data. This study period was from January 1, 2015 to
December 31, 2016. The Mississippi Medicaid administrative database contains a beneficiary
master file, inpatient claims file, outpatient claims file, medical claims file, and prescription
claims file. Each of these files were used for this study.

Study Sample
Inclusion Criteria
Objective 1 and 2:
•

Patients with at least one medical claim for a non-ED dental event.

•

Patients with a claim for an opioid analgesic prescription medication within 3 days of a
dental event were included in the opioid use group.

Objective 3:
•

Patients with a claim for ED visit with dental disease diagnoses.

•

Patients with a claim for an opioid analgesic prescription medication within 24 hours of
the ED visit were included in the opioid use group.
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Exclusion Criteria
Patients that were dual eligible (patients with both Medicare and Medicaid coverage), in hospice
care or long-term care facilities were excluded from the analysis.

Study Measures and Operationalization
Demographic/ Patient variables
Patient demographic information was obtained from the Medicaid beneficiary Masterfile. The
demographic variables included in the study were:
i.

Age: 0-18 years, 19-44 years, 45-59 years, and 60+ years

ii.

Gender: Male or Female

iii.

Race: White/Caucasian, Black/African American, Hispanic, Native American, Other

Opioid Medication/Drug Variables
i.

Identification of opioid analgesic variables
To identify opioid prescriptions, national drug codes (NDC) for opioid medications were
identified in the Medicaid data using the NDC Masterfile utilizing therapeutic categories
that contains all prescription opioids, strength, dosage, form, and formulation for each
drug prescribed. The quantity, number of days supplied, and the date the
prescription was written and dispensed, were included for each prescription.

ii.

Morphine equivalent dose
Morphine Equivalent Daily Dose (MEDD) was used to report the relative daily
strength of the opioid analgesics prescribed for dental events. MEDD is calculated by
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multiplying the quantity of the prescription for each day of supply by its strength (in
milligram equivalents) and a conversion factor, specific to the drug prescribed (Braden et
al., 2009). The CDC has a cautionary warning on the prescription of opioids with
morphine equivalents greater than 50 MEDD/day (Dowell, D., Haegerich, T. M., &
Chou, R., 2016). In this study, we subdivided MEDD into 4 categories: Less than 50
MEDD, 50 to 89 MEDD, 90 to 119 MEDD, and greater than or equal to 120 MEDD.
iii.

Number of days supplied
Number of days supplied signifies the number of days the opioid medication was
intended for use. Due to the acute nature of dental pain, this variable was measured from
the pharmacy claims and categorized into 0-3 days, 4-7 days, 8-15 days, 16-30 days and
greater than 30 days.

iv.

Emergency department visits
Emergency department(ED) visits were identified using the procedural codes 9928199285. This represents the visit code by severity of the situation and extensiveness of
care evaluation.

v.

Provider categories:
General Practice Dentists
Pediatric Dentists
Orthodontists, Oral and Maxillofacial surgeons
MD-Other: Student trainee/Internists, Physicians/Dentists without a specific self-reported
identifier

Dental Event Variables
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Ten dental visit events were identified using ICD-9-CM and ICD-10-CM codes. The list
of ICD-9 and ICD-10 codes for the dental procedures of interest used in this study can be found
in Appendix B.
International Classification of Diseases (ICD) codes are a set of codes developed by the
National Center for Health Statistics (NCHS). ICD codes serve as a useful tool in the
classification of morbidity data for health records, medical care review, and ambulatory and
other health care programs, as well as for basic health statistics. ICD codes are used to classify
diseases and a wide variety of signs, symptoms, abnormal findings, complaints, social
circumstances and external causes of injury or disease. Nearly every health condition can be
assigned to a unique category and given a code, up to six characters long.
The United States Department of Health & Human Services and the Centers for
Medicare and Medicaid Services (CMS) created ICD-9-CM as an extension of the Ninth
Revision, International Classification of Diseases (ICD-9), which the World Health
Organization (WHO) established to track mortality statistics across the world. ICD-10-CM is
the US clinical modification of the World Health Organization’s ICD-10. ICD-9 codes will also
be used because ICD-10 codes were not implemented until October 2015. Both ICD-9 and ICD10 codes were used to identify the various dental diagnosis made by the dental providers. A list
of the ICD-9 and ICD-10 codes for dental procedures were developed using the Vermont
Medicaid Portal dental ICD code database and ICD-10 Code Search (Vermont Medicaid, 2015;
ICD-10 Code Search, 2017).

Statistical Analysis
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All data were analyzed using the Statistical Analysis System (SAS®) version 9.5 (SAS
Institute Inc., Cary, NC). An a priori alpha level of 0.05 was used to evaluate significance for
all analyses.
Objective 1: Prevalence of opioid analgesics prescribing for dental related visits in the
Mississippi Medicaid population
Descriptive statistics
i.

Demographic/Patient level information: Frequencies and percentages were
calculated for all variables (age, gender, race/ethnicity), mean and standard deviation
was also computed for age (continuous variable).

ii.

Dental event information: For each dental event category, the total number and
percentage of events in each category, opioid analgesic prescription rate per event
category, morphine equivalent daily dose (MEDD) categorized into (less than 50, 50
to 89, 90 to 119, greater than 120) in each category, mean and standard deviation of
opioid medication days’ supply per category were provided.

iii.

Medication level information: Frequency and percentages of days supply of
medication and type of opioid medication prescribed per dental visit event category.

PROC FREQ, PROC MEANS and PROC TABULATE procedures in SAS® was used to
develop frequency tabulations.
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Objective 2: Predictors of receiving opioid analgesics following a dental related event
among Mississippi Medicaid beneficiaries
A logistic regression model was developed to assess the relationship between predictors
(patient/sociodemographic variables) and dental events.
In the first logistic regression model, the predictors were age, race, gender, dental visit
event category and prescribing dentist specialty. The dependent variable was the odds of
receiving an opioid following a dental related visit.
Another logistic regression model was conducted with the dependent variable being
receiving an opioid with a Morphine Equivalent Daily Dose (MEDD) greater than 25 (median
value), following a dental visit event. The predictors were age, race, gender, dental visit event
category and prescribing dental specialty.
The PROC LOGISTIC procedure in SAS® was used to logistic regression model. Odds
ratios, 95% confidence intervals and p-values were obtained for the logistic regression models.
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Objective 3: Prevalence of opioid analgesic prescription for dental related emergency
department (ED) visits
i.

Demographic/Patient level information: Frequencies and percentages were
calculated for all variables (age, gender, race/ethnicity), mean and standard deviation
was also computed for the continuous variable (age).

ii.

Dental event level information: For each dental event category, the total number and
percentage of events in each category, opioid analgesic prescription rate per disease
category, morphine equivalent daily dose (MEDD) categorized into (less than 50,
50-89, 90-119, greater than 120) in each event category, mean and standard
deviation of opioid medication days’ supply per category was provided.

iii.

Medication level information: Frequency and percentages of days supply of
medication and type of opioid medication prescribed per dental visit event category
were calculated.

PROC FREQ, PROC MEANS and PROC TABULATE procedures in SAS® was used to
develop frequency tabulations.
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RESULTS

Study Sample
During the period of January 1, 2015 to December 31, 2016 in the Mississippi Medicaid
data, a total of 12,388 beneficiaries had at least one dental event during the study period, and
2,673 beneficiaries had a claim for an opioid within 3 days of a dental visit. Figure 1 shows the
sample selection chart for patient level information.
Beneficiaries
identified with at least
one dental event in the
study period
12,388

Beneficiaries
with a claim for
an opioid
analgesic
medication
within 3 days

12,388

Beneficiaries
without a claim
for an opioid
analgesic
medication
within 3 days

2,673

9,715

Figure 1: Sample selection chart (Patient level information)
12,388
12,388

OBJECTIVE 1
Prevalence of opioid analgesics prescribing for non-ED dental related visits in the Mississippi
Medicaid population.
i.

Patient level information
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African Americans accounted for 58.98% of the population, while Caucasians made up
34.40% of the population. The majority of the sample was female (58.04%) and 67.63% of the
sample population was below the age of 18, while 27.66% of the population was between the
ages of 19 to 44 years. Table 1 provides frequency tabulations for the sample population
demographic characteristics.

Table 1: Sample population demographic characteristics
Demographic Characteristics
N=12,388
Age (Mean= 16.37, SD=15.27)
0-18 years
19-44 years
45-59 years

n

60+ years
Race/Ethnicity
Caucasian
African American
Hispanic
American Indian
Other
Gender
Female
Male

%

8,378
3,426
495

67.63
27.66
4.00

89

0.72

4,261
7,307
233
86
501

34.40
58.98
1.88
0.69
4.04

7,190
5,198

58.04
41.96

Overall, 21.58% of the beneficiaries who had at least one dental event received an opioid
analgesic prescription. Among adults aged between 19 years to 44 years, 45.83% of patients who
had at least one dental event received an opioid medication within 3 days. Among adults aged
between 45 years to 59 years, 38.79% received an opioid medication within 3 days while only
26.97% adults aged above 60 years received an opioid within 3 days following a dental visit.
Children below the age of 18 received the lowest proportion of opioids, among children below
18 years, only 10.59% received an opioid medication within 3 days. Table 2 provides the
proportion of patients receiving an opioid within 3 days following a dental visit.
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Table 2: Proportion of patients receiving opioid medication within 3 days following a dental
visit
Demographic Characteristics
All
Age (Mean= 16.37, SD=15.27)
0-18 years
19-44 years
45-59 years
60+ years
Race/Ethnicity
Caucasian
African American
Hispanic

Total population
n
12,388

American Indian
Other

Proportion receiving an opioid
n
%
2,673
21.58

8,378
3,426
495
89

887
1,570
192
24

10.59
45.83
38.79
26.97

4,261
7,307
233

920
1602
44

21.59
21.92
18.88

86
501

5
102

5.81
20.36

7,190
5,198

1,875
798

26.08
15.35

Gender
Female
Male

ii.

Dental event level information
Of the 12,388 beneficiaries who met the inclusion criteria, a total of 16,409 dental events

were identified. Dental events were categorized into ten distinct categories. Overall, 26.70% of
the dental events had an associated opioid analgesic prescription within 3 days. Extraction/loss of
tooth events accounted for the highest rate of opioid prescriptions (54.71%), while 42.37% of
root canal and endodontic treatment procedures were associated with the prescription for an
opioid medication.
Cleaning, preventive and cleaning procedures category had the highest opioid average
days’ supply with a mean of 15.78 days. Dental caries category had an average days supply of
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5.61 days while root canal procedures had an opioid average days supply of 10.68 days. Overall,
across all dental conditions, the average days’ supply of opioid medication was 5.5 days.
Dental caries was the most common dental disease category accounting for 53.70% of the
total dental disease events followed by diseases of the pulp with 17.91% of the total dental
events. Majority of extraction and loss of tooth events had an associated opioid analgesic
prescription (54.71%) and it represented the dental disease category with the highest rate of
opioid prescribing following a visit for a dental event. About 42% of dental events involving root
canal and endodontic treatment procedures were associated with an opioid medication. Summary
statistics for the opioid prescription rates among the disease categories as well as the mean,
Dental Events

All
Cleaning, Preventative and Fitting
procedures
Disorders of Tooth Development

Number of events
per category
n
16,409
402
661

Embedded and Impacted tooth

1,571

Dental Caries

8,811

Abrasion and Attrition of the teeth
Diseases of the pulp
Gum disease, Periodontitis and Gingivitis.
Extraction procedures, Loss of tooth
Root Canal and Endodontic Treatment

66
2,939
513
1,307
118

Developmental Cysts
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Proportion
Days supply
associated with an
of opioid
Opioid medication
%
n
%
Mean(SD)
100.00
4,382
26.70
5.50 (5.57)
2.44
64
15.92
15.78(11.12)
4.03
52
7.87
7.15 (5.99)
9.57
286
18.20
4.45 (3.52)
53.70
2,055
23.32
5.61 (6.13)
0.40
22
33.33
4.68 (5.85)
17.91
976
33.21
5.83 (6.86)
12.51
160
31.19
6.40 (7.07)
7.97
715
54.71
5.74 (6.53)
0.72
50
42.37
10.68 (6.08)
0.13
2
9.52
5.50 (2.12)

standard deviation days supply of opioid medication are provided in Table 3.
Table 3: Opioid prescription rate and mean days supply for different dental event categories
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Table 4 reports the morphine equivalents doses of opioid prescribed for the ten dental
event categories by the four categories. MEDD was categorized into four categories: less than
50, 50 to 89, 90 to 119, greater than 120. Among all dental events, 11.39% of received an opioid
with a morphine equivalent daily dose (MEDD) greater than 50. About 238 (16.43%) of opioid
prescriptions for embedded and impacted tooth events were prescribed doses with morphine
equivalent between 50 and 89. Almost a quarter (13.44%) of opioid prescriptions for abrasions
and attrition events had an opioid medication with a morphine equivalent greater than 50, while
approximately 11% of dental caries events had an opioid prescribed with a MEDD greater than
50. The number and proportion of disease events in each morphine equivalent category are
reported in Table 4.

Table 4: Morphine equivalent daily dose of opioid prescriptions for different dental events
Dental events

All
Cleaning, Preventative and Fitting
procedures
Disorders of Tooth Development

Less than 50
n
%
3,858 88.04

Morphine Equivalent Daily Dose
50 - 89
90 - 119
Greater than 120
n
%
n
%
n
%
469 10.70 38
0.70
17
0.39

53

82.81

7

10.94

1

1.56

3

4.69

46

88.46

6

11.54

0

0.00

0

0.00

238

83.22

47

16.43

1

0.35

0

0.00

1,822
19
861

88.66
86.36
88.22

206
3
104

10.02
13.64
10.66

19
0
9

0.92
0.00
0.82

8
0
3

0.39
0.00
0.31

Gum disease, Periodontitis and
Gingivitis.
Extraction procedures, Loss of tooth

146

91.25

13

8.13

0

0.00

1

0.63

622

86.99

83

11.61

8

1.12

2

0.28

Root Canal and Endodontic
Treatment
Developmental Cysts

49

98.00

0

0.00

1

2.00

0

0.00

2

100.00

0

0.00

0

0.00

0

0.00

Embedded and Impacted tooth
Dental Caries
Abrasion and Attrition of the teeth
Diseases of the pulp
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iii.

Drug level information
Forty seven percent of all prescriptions were for durations less than 3 days while 83.66%

of the prescription had durations less than 7 days and over 93% of the prescriptions were for
durations less than or equal to 15 days. Table 5 shows the days supply categories and
frequencies for all prescription opioid medications.

Table 5: Days supply of all prescription opioid medications
Days’ supply
0-3 days
4-7 days
8-15 days
16-30 days
> 30 days

n

%

2,077
1,589
412
290
14

47.40
36.26
9.40
6.62
0.32

Table 6 reports the most frequently prescribed opioids for dental related events.
Hydrocodone, codeine and tramadol collectively accounted for 90.74% of opioid medications
prescribed for dental related disorders and were the most commonly prescribed medication of
opioids for dental related events.
Table 6: Most frequently prescribed opioids for dental related events
Generic Name

n (%)

Acetaminophen-Hydrocodone
Acetaminophen- Codeine

2,536 (57.87)
1,048 (23.92)

Tramadol
Acetaminophen- Oxycodone
Acetaminophen- Tramadol
Oxycodone
Fentanyl
Morphine
Meperidine
Hydromorphone
Hydrocodone- Ibuprofen
Buprenorphine
Oxymorphone

392 (8.95)
288 (6.57)
35 (0.80)
30(0.68)
17 (0.39)
15 (0.34)
9 (0.21)
3 (0.07)
4 (0.09)
1 (0.02)
2 (0.05)
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Morphine- Naltrexone
Butorphanol

1 (0.02)
1 (0.02)

OBJECTIVE 2
Predictors of receiving opioid analgesics following dental related events among
Mississippi Medicaid beneficiaries
A logistic regression model using PROC LOGISTIC command in SAS to assess the
association between the predictor variables (demographic variables, dental visit events and dental
provider categories) and odds of receiving an opioid medication following a dental visit.
Race/Ethnicity was not a significant predictor of receiving an opioid following a dental visit.
Gender was also not a significant predictor of opioid prescriptions. However, age was significant
with patients 18 years or younger having a lower odds of receiving an opioid in comparison to
patients ages 19 to 45 years (OR= 0.235, 95% CI: 0.213-0.261, P<0.0001).
Regarding dental visit events, cleaning, fitting and preventative procedures (the reference
category), beneficiaries who had a disease of the pulp had a higher odds of receiving an opioid
analgesic following a dental visit (OR = 2.114, 95% CI: 1.483-3.012, P<0.0001), beneficiaries
with gum diseases, periodontitis and gingivitis had a higher odd of receiving an opioid analgesic
(OR = 2.852, 95% CI: 1.564-3.587, p< 0.0001), and beneficiaries who had had an extraction
procedure and loss of tooth had a higher odd of receiving an opioid analgesic (OR= 2.852, 95%
CI: 1.981-4.105, p<0.0001).
Regarding dental providers, general practice dentists had a higher odd of prescribing
opioid analgesics following a dental visit in comparison to pediatric dentists (OR=2.336, 95%
CI: 2.047-2.666, P<0.0001). Table 7 presents the adjusted odds ratio and 95% confidence
interval for patient variables as well as disease variables associated with an opioid prescription
after adjusting for differential prescribing patterns by the providers/provider clustering.
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Table 7: Logistic regression examining predictors of being prescribed an opioid
Predictors

Odds Ratio

Race/Ethnicity
Caucasian
Hispanic/Latino
American Indian/Native American
African American
Other

95% Confidence
Interval

P-Value

Reference

Reference

Reference

1.402
1.522

0.998-1.970
0.430-5.380

0.0513
0.5148

0.973

0.892-1.063

0.5464

0.972

0.768-1.232

0.8169

Reference
0.953

Reference
0.866-1.048

Reference
0.3178

0.235

0.213-0.261

<0.0001

Reference
1.047

Reference
0.881-1.245

Reference
0.6029

0.896

0.576-1.394

0.6273

Reference
0.952
0.722
1.267
1.778
2.114

Reference
0.587-1.542
0.498-1.048
0.894-1.795
0.845-3.740
1.483-3.012

Reference
0.8406
0.0863
0.1837
0.1297
<0.0001

2.852

1.564-3.587

<0.0001

2.852
1.675
0.572

1.981-4.105
0.987-2.841
0.119-2.751

<0.0001
0.0559
0.4861

2.336
Reference
1.084
1.080

2.047-2.666
Reference
0.956-1.228
0.921-1.265

<0.0001
Reference
0.2084
0.3442

Gender
Male
Female
Age
0-18
19-45
46-59
60+
Dental events
Cleaning, preventative and fitting
procedures
Disorders of tooth development
Embedded and Impacted tooth
Dental Caries
Abrasion and attrition of the teeth
Diseases of the pulp
Gum diseases, periodontitis and
gingivitis
Extraction procedure, Loss of tooth
Root canal and endodontic treatment
Developmental cysts of the mouth
Dental provider
General practice dentists
Pediatric dentists
Oral and Maxillofacial surgeons
Other dental providers
*P <0.05; ** P <0.0001
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Table 8 shows results of a logistic regression model using PROC LOGISTIC to show the
association between the predictor variables (demographic variables, dental visit events and dental
provider categories) with the outcome of the odds of receiving an opioid medication with a
morphine equivalent greater than 25 MEDD (median value) following a dental related visit.
African Americans had a slightly lower odd of receiving an opioid medication with a
morphine equivalent greater than 25 compared to Caucasians (OR= 0.867, 95% CI: 0.784-0.970,
P= 0.0115) while Hispanics/Latinos have a lower odd of receiving an opioid medication with a
morphine equivalent greater than 25 compared to Caucasians (OR= 0.360, 95% CI: 0.164-0.790,
P= 0.0109). Patients aged 18 years or below had a much lower odd (OR=0.097, 95% CI: 0.0830.112, P<0.0001) of receiving opioid with a morphine equivalent greater than 25.
Regarding dental events and the odd of receiving an opioid with a morphine equivalent
higher than 25, compared to the reference category (cleaning, fitting and preventative
procedures), patients with abrasion and attrition of the teeth had a higher odd (OR= 2.585, 95%
CI: 1.155-5.787, P=0.0209), patients with diseases of the pulp had a higher odd (OR= 1.877,
95% CI: 1.211-2.908, P=0.0049), gum diseases periodontitis and gingivitis (OR =2.764, 95% CI:
1.672-4.568, P<0.0001), extraction and loss of tooth procedure (OR= 2.100 95% CI: 1.3463.278, P=0.0011), root canal and extraction procedures (OR=2.757, 95% CI: 1.524-4.987,
P=0.0008) have a higher odd of receiving an opioid medication with a morphine equivalent

greater than 25.
Regarding dental providers, compared to the reference category of pediatric dentists, general
practice dentists had a higher odd of prescribing an opioid with a morphine equivalent greater
than 25 (OR=3.734, 95% CI: 3.181-4.382, p<0.0001), oral and maxillofacial surgeons had a
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higher odd of prescribing opioids with a morphine equivalent greater than 25 (OR=1.734, 95%
CI: 1.486-2.023, P<0.0001).
Table 8: Logistic regression examining association between predictor variables and the odds of
being prescribed an opioid with morphine equivalent dose greater than 25
Predictors

Odds Ratio

Race/Ethnicity
Caucasian
Hispanic/Latino
American Indian/Native American
African American
Other

95% Confidence
Interval

P-Value

Reference

Reference

Reference

0.360
0.403

0.164-0.790
0.048-3.409

0.0109*
0.4042

0.872

0.784-0.970

0.0115*

0.845

0.637-1.121

0.2426

Reference
0.989

Reference
0.873-1.119

Reference
0.8557

0.097

0.083-0.112

<0.0001**

Reference
0.870

Reference
0.717-1.056

Reference
0.1601

1.098

0.680-1.771

0.7021

Reference
1.011
1.241
1.219
2.585
1.877

Reference
0.548-1.866
0.784-1.963
0.791-1.880
1.155-5.787
1.211-2.908

Reference
0.9713
0.3565
0.3698
0.0209*
0.0049*

2.764

1.672-4.568

<0.0001**

2.100
2.757
1.515

1.346-3.278
1.524-4.987
0.289-7.930

0.0011*
0.0008*
0.6229

3.734
Reference
1.734
1.298

3.181-4.382
Reference
1.486-2.023
1.071-1.573

<0.0001**
Reference
<0.0001**
0.0079*

Gender
Male
Female
Age
0-18
19-45
46-59
60+
Dental events
Cleaning, preventative and fitting
procedures
Disorders of tooth development
Embedded and Impacted tooth
Dental Caries
Abrasion and attrition of the teeth
Diseases of the pulp
Gum diseases, periodontitis and
gingivitis
Extraction procedure, Loss of tooth
Root canal and endodontic treatment
Developmental cysts of the mouth
Dental provider
General practice dentists
Pediatric dentists
Oral and maxillofacial surgeons
Other dental providers
*P <0.05; ** P <0.0001
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OBJECTIVE 3
Prevalence of opioid analgesics prescribing for dental related emergency departments (ED)
related visits in the Mississippi Medicaid population
Study sample
In the 2015 and 2016 Mississippi division of Medicaid data, a total of 2,574 beneficiaries
had a dental related ED visit, and among these, 1,176 had an opioid prescription claim within 24
hours. Figure 2 shows the sample selection chart for patient level information.
Beneficiaries identified
with an ED visit related to
a dental event in the study
period
2,574

Beneficiaries with a
claim for an opioid
analgesic medication
within 24 hours

Beneficiaries without a
claim for an opioid
analgesic medication
within 24 hours

12,388

1,176

1,398

Figure 2: Sample
12,388selection chart (Patient level information) for ED related visits

1. Demographic/Patient level information dental related ED visits
African Americans accounted for a little over 60% of the population using the emergency
department for dental visits, while Caucasians made up 35.04% of the population. Females
accounted for 77.74% of beneficiaries using the ED for dental related events. Only 14.41%
of the sample population was 18 years or younger, while 75.87% of the population is
between the ages of 19 to 44 years. Table 9 reports descriptive statistics of the total
population using the ED for dental events.
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Table 9: Sample characteristics of patients using ED for dental related events.
Demographic Characteristics
n=2,574
Age (Mean= 29.71, SD=11.15)
0-18 years
19-44 years
45-59 years
60+ years
Race/Ethnicity
Caucasian
African American
Hispanic
American Indian
Other

n

%

371
1,953
224
26

14.41
75.87
8.70
1.01

902
1,571
13

35.04
61.03
0.51

5
83

0.19
3.22

2,001
573

77.74
22.26

Gender
Female
Male

Approximately 45% of African Americans who used the ED for dental related events
were prescribed an opioid analgesic medication within 24 hours, while the rate of prescription
among Caucasians was 46.78%. Among patients 18 or younger who used the ED for dental
related events, more than half (51.2%) received an opioid analgesic medication while
approximately 45% of patients aged 19-44 years who used the ED for a dental related event
received an opioid medication. About 48% of males using the ED for dental related events
received an opioid analgesic medication while 45% of females received an opioid. Table 10
provides the proportion of patients receiving an opioid within 24 hours following at least one
dental ED visit.
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Table 10: Proportion of patients receiving an opioid within 24 hours following a dental ED visit
Demographic Characteristics
n=2,574
All
Age (Mean= 29.71, SD=11.15)
0-18 years
19-44 years
45-59 years
60+ years
Race/Ethnicity
Caucasian
African American
Hispanic
American Indian
Other
Gender
Female
Male

Total Population
n
2,574

Proportion receiving an opioid
n
%
1,176
45.70

371
1,953
224
26

190
883
95
8

51.21
45.21
42.41
30.77

902
1,571
13
5
83

422
708
7
2
37

46.78
45.07
53.85
40.00
44.58

2001
573

902
274

45.08
47.82

2. Event level information for ED related dental visits
A total of 3,417 dental events related to ED visits were identified. Dental events were
categorized into ten distinct categories. Summary statistics for the opioid prescription rates
among the disease categories encountered in the ED as well as the mean and standard
deviation of days supply of opioid medication were calculated.
Overall, 41.59% of all dental related visits to the emergency room had an associated
opioid medication prescription. Approximately 42% of ED dental events related to dental
caries had an associated opioid prescription, while 48% of ED visits related to gum disease
and gingivitis received an opioid medication. Dental caries was the most common event
category encountered with 39.04% of the total dental disease events in the ED followed by
diseases of the pulp with 33.60% of dental ED visits. Table 11 reports opioid prescription
rate and mean days supply for dental related ED visits.
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Table 11: Opioid prescription rate and mean days supply for dental related ED visits
Dental event category

Number of events per
category

n
3,417

%
100.0
0

2

0.06

1

7

0.20

4

47

1.38

20

1,334

39.04

563

24

0.70

5

1,148

33.60

469

100

2.93

48

743

21.74

307

11

0.32

4

1

0.03

0

All
Cleaning, Preventative and Fitting
procedures
Disorders of Tooth Development

Proportion
associated with
an Opioid
medication
n
%
1,421

Embedded and Impacted tooth
Dental Caries
Abrasion and Attrition of the teeth
Diseases of the pulp
Gum disease, Periodontitis and
Gingivitis.
Extraction procedures, Loss of
tooth
Root Canal and Endodontic
Treatment
Developmental Cysts

41.59

Days
supply of
opioid
Mean(SD)
5.50
(5.57)

50.00 15.00 (-)
3.75
57.14
(2.87)
3.40
42.55
(2.13)
4.98
42.20
(5.45)
3.40
20.83
(1.67)
4.83
40.85
(5.23)
6.48
48.00
(7.42)
5.06
41.32
(5.36)
4.50
36.36
(2.08)
- (-)
0.00

Table 12 reports the morphine equivalents(MEDD) of opioid prescribed for ED visits
related to dental event categories subdivided into four morphine equivalents: less than 50, 50 to
89, 90 to119, greater than 120. The number and proportion of events in each morphine
equivalent category is also shown below in Table 12.
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Table 12: Morphine equivalent daily dose (MEDD) of opioid prescriptions for ED related dental
diseases
Dental Disease Category

All procedures
Cleaning, Preventative and Fitting
procedures
Disorders of Tooth Development

Less than 50
n
%
1,264
88.95

Morphine Equivalent Daily Dose
50 - 89
90 - 119
Greater than 120
n
%
n
%
n
%
145 10.20
11
0.77
1
0.07

1

100.00

0

0.00

0

0.00

0

0.00

4

100.00

0

0.00

0

0.00

0

0.00

15

75.00

5

25.00

0

0.00

0

0.00

498

88.45

63

11.19

2

0.36

0

0.00

3

60.00

2

40.00

0

0.00

0

0.00

419

89.34

47

10.02

3

0.64

0

0.00

45

93.75

3

6.25

0

0.00

0

0.00

275

89.58

25

8.14

6

1.95

1

0.33

Root Canal and Endodontic Treatment

4

100.00

0

0.00

0

0.00

0

0.00

Developmental Cysts

0

0.00

0

0.00

0

0.00

0

0.00

Embedded and Impacted tooth
Dental Caries
Abrasion and Attrition of the teeth
Diseases of the pulp
Gum disease, Periodontitis and
Gingivitis.
Extraction procedures, Loss of tooth

3. Drug level information on dental related ED visits
Regarding opioid medication variables, approximately 53% of all prescriptions in the ED
were for durations less than 3 days while 87.40% of the prescriptions following an ED visit had
durations less than 7 days. Table 13 reports the days’ supply of prescribed opioid medications
following a dental related E.D visit.
Table 13: Days’ supply of prescribed opioid medications for
dental related ED visits
Days’ supply

n

(%)

0-3 days
4-7 days

754
488

53.06
34.34

8-15 days

119

8.37

47

16-30 days
> 30 days

57

4.01

3

0.21

Hydrocodone accounted for about 62% of opioid prescription in the ED, while codeine
was prescribed for about 17% of opioid prescriptions following a dental related ED visit.
Hydrocodone, Codeine and Tramadol collectively accounted for 92.58% of opioid medications
prescribed for dental related disorders following an ED visit. Table 14 reports the most
frequently prescribed opioids following dental related ED visits.

Table 14: Most frequently prescribed opioids following dental related ED visits
Generic Name

n (%)
886 (62.35)

Acetaminophen-Hydrocodone

238 (16.75)

Acetaminophen- Codeine

192(13.51)

Tramadol

75(5.28)

Acetaminophen- Oxycodone

17 (1.20)

Acetaminophen- Tramadol
Hydrocodone- Ibuprofen

5 (0.35)

Oxycodone

3 (0.21)

Morphine

2 (0.14)

Meperidine

1 (0.07)
1 (0.03)

Fentanyl
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CHAPTER V
DISCUSSION
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OBJECTIVE 1
Prevalence of opioid analgesics prescribing for non-ED dental related visits in the Mississippi
Medicaid population
In this study, we sought to assess various trends in opioid analgesic prescribing for dental
related visits using the Mississippi Medicaid database. The results of the study indicate that
dental related problems are a prominent source of opioid prescribing. Based on previous research
by Levy et al, a study using IMS national prescription audit data on opioid prescription volume
by specialty, showed that dentists prescribed 6.4% of all opioids; and this translates to millions
of prescriptions (Levy, Paulozzi, Mack, & Jones, 2015).
In our study, we found that dental caries was the most frequently encountered dental
disease category. The following dental event categories: (1) tooth extraction procedures and
other conditions involving loss of tooth, (2) root canal treatment and endodontic therapies, (3)
embedded and impacted tooth, (4) diseases of the pulp and (5) dental caries had a higher odd of
receiving an opioid analgesic prescription following a visit, compared to cleaning and
preventative procedures. These observations are consistent with other research showing that root
canal procedures, periodontics’ treatment had a high odd of receiving an opioid prescription per
visit to the dentist (Steinmetz et al 2017).
Our study also suggests a lower rate of opioid prescribing among children 18 years and
younger. In this study, the rate of opioid prescriptions ages 18 years and younger was about
10.59%. This finding is in line with another study conducted using the National Medicaid
analytic extract files to assess the proportion of Medicaid patients dispensed opioids following
surgical extraction of teeth. In the 2000-2010 data, they found that 14% of children under 13 and
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61% of children under 18 years of age received of opioid prescription for dental extraction
procedures. (Baker, J. A., Avorn, J., Levin, R., & Bateman, B. T., 2016). Another study
conducted in Canada reported that 50% of children in their study received codeine for less than 3
days (Etminan, M., Nouri, M. R., Sodhi, M., & Carleton, B. C., 2017). The rate of opioid
prescribing among children in our study is lower (11%) than other studies showing similar rates
of opioid prescriptions among children. However, this could be due to the increased awareness
regarding the danger of opioid prescription in the United States.
In our study, morphine equivalent dose of opioids prescribed to patients following dental
procedures indicates that the majority of patients in most disease categories received an opioid
with a morphine equivalent dose less than 50. However, a small proportion of patients received
opioids with morphine equivalent doses greater than 50 for dental events. The Centers for
Disease Control and Prevention (CDC) has issued guidelines which encourage clinicians to use
caution when prescribing opioids at any dosage. Additionally, they should carefully reassess
evidence of individual benefits and risks when considering increasing dosage to 50 morphine
milligram equivalents or higher (Dowell, D., Haegerich, T. M., & Chou, R., 2016).
In our study, drug level information indicated that hydrocodone, codeine and tramadol
were the most frequently prescribed opioids following a dental related condition. This finding is
consistent with previous studies on the most frequently prescribed opioids following dental
extraction which showed that hydrocodone, oxycodone, propoxyphene and codeine as the most
commonly prescribed opioids following tooth extraction (Baker, J. A., Avorn, J., Levin, R., &
Bateman, B. T., 2016). These results indicate the need to provide adequate information to
dentists to prevent inappropriate prescribing of opioids to patients who may otherwise be
adequately treated for pain with other classes of analgesics.
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OBJECTIVE 2
Predictors of receiving opioid analgesics following dental related events among Mississippi
Medicaid beneficiaries
A logistic regression model predicting the odds of receiving an opioid medication for
dental visits was developed. Our findings indicate that the prescribing of opioid analgesic
medication for dental related pain and the odds of receiving an opioid medication is higher
among Hispanics, patients with diseases of the pulp, patients that have undergone a tooth
extraction procedure or a root canal treatment and patients with gum disease or periodontitis.
This observation is in line with previous literature on opioid analgesic prescribing for dental
diseases and socioeconomic status showing that minorities had a higher odd of opioid
prescriptions for dental diseases (Steinmetz et al, 2017). Our study indicates that regarding
providers, compared to the reference category of pediatric dentists, general practice dentists, oral
and maxillofacial surgeons had a higher odd of prescribing opioids.
A logistic regression analysis was modeled to predict the odds of receiving an opioid
medication with a morphine equivalent dose greater than 25 morphine equivalent daily dose
which was the median morphine equivalent in the study population. Our findings indicated that
beneficiaries 18 years or younger, had a lower odd of receiving an opioid with a MEDD of 25 or
more, while patients with diseases of the pulp, gum diseases or had undergone an extraction
procedure have a higher odd of receiving an opioid medication with a dose greater than 25
morphine equivalents. Furthermore, opioid prescribing dosage is important due to CDC
guidelines on clinicians being encouraged to understand the benefits and risks when considering
increasing opioid dosage to 50 morphine milligram equivalents (MME)/day or greater (Dowell,
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D., Haegerich, T. M., & Chou, R., 2016). Our study indicates that regarding providers, compared
to the reference category of pediatric dentists, general practice dentists, oral and maxillofacial
surgeons had a higher odd of prescribing opioids.
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OBJECTIVE 3
Prevalence of opioid analgesics prescribing for emergency departments (ED) related visits in
the Mississippi Medicaid population
In this study, we used data from Mississippi Medicaid to assess various trends in opioid
use following emergency department (ED) visits for dental conditions. In our study, dental caries
accounted for the most frequent dental disease category encountered in ED visits. Gum diseases,
loss of tooth and extraction procedures, dental caries, diseases of the pulp all accounted for high
proportion of opioid prescriptions following an ED visit. An observational multicenter study on
general ED visits showed that among patients whose chief complaint and primary discharge
diagnosis was associated with an opioid medication after an ED visit, 5.9% were related to dental
pain and 6.2% was related to a dental or oral issue representing 12.1% of total emergency visits
due to pain (Hoppe, J. A., Nelson, L. S., Perrone, J., Weiner, S. G., 2015). This indicates a
potential reliance on emergency departments for treatment by some patients with dental
problems.
Our study also suggests a low rate of opioid prescription following ED use for dental pain
among children ages 18 years or younger (14.41%). Approximately 76% of patients receiving
opioids following emergency department visit for dental related diseases were between the ages
of 19 and 44 years. This trend observed in this study is supported by prior research studies which
reported that most patients using ED services associated with dental pain were young adults
between the ages of 19 and 33 years (Okunseri, C., Okunseri, E., Xiang, Q., Thorpe, J. M., &
Szabo, A., 2014).
Morphine equivalent dose of opioids prescribed to patients following ED dental
procedures also shows that a clear majority of patients in most disease categories received an
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opioid with a morphine equivalent dose less than 50. However, a small proportion of patients
received opioids with morphine equivalent doses greater than 50 after an ED visit. Our study
found that hydrocodone was the most commonly prescribed opioid analgesic for ED visits was
hydrocodone (62.35%) followed by codeine (16.75%) and finally tramadol (13.51%). A previous
study on types of opioid analgesics prescribed in the ED revealed that the most frequently
prescribed opioid medications in the ER are oxycodone (52.3%), hydrocodone (40.9%), and
codeine (4.8%) and that 90% of prescribed opioids were combination products with analgesics
like ibuprofen and acetaminophen (Hoppe, J. A., Nelson, L. S., Perrone, J., Weiner, S. G. 2015).

Limitations
There are several limitations to the study. First, the study was conducted using Medicaid
administrative claims data and therefore there is a possibility of misclassification of dental
diseases due to coding errors during claims processing. Also, it is possible to have some opioid
analgesic prescription claims not related to dental visits included in the study, possibly due to
multiple visits in the same time frame by beneficiaries to multiple providers in the same hospital
including dentists. Days’ supply of opioid used in the calculation could be altered by the
pharmacy processing claim to ease payment by insurance thereby potentially confounding the
morphine equivalent dosage calculations. Classification of race/ethnicity was determined by
hospital staff based on perception of the hospital staff. Additionally, our findings might not be
generalizable to the general population or representative of opioid utilization in the general
population due to the data being state specific with a population that is generally below the
poverty line.
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Conclusions
This study is significant because it identifies and characterizes opioid prescription use in
dental conditions and gives us an understanding of how specific dental events and demographic
factors that contribute to receiving opioid prescriptions following a dental visit in the ED and
non-ED setting.
Due to the current CDC warning of provider caution in prescribing opioids with dosage
greater than 50 morphine equivalents, this study identifies predictors of high opioid dosage in
dental patients and utilizes statistical techniques to assess the relationship between
sociodemographic and dental disease variables and high opioid doses for dental related events.
In conclusion, this study has a broader policy implication for the state of Mississippi
regarding opioid abuse and misuse, drug utilization trend monitoring and curtailing opioid abuse
by broadening the lens to the field of dentistry.
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Appendix A: FDA approved opioid analgesic medications
Generic Name

Brand Names (examples)

1.

Alfentanil

Alfenta

2.

Buprenorphine

Belbuca, Buprenex, Butrans

3.

Butorphanol

No brand name currently marketed

4.

Codeine

Fioricet w/ codeine, Fiorinal w/ codeine, Soma Compound
w/ codeine, Tylenol w/ codeine

5.

Dihydrocodeine

Synalgos-DC

6.

Fentanyl

Abstral, Actiq, Duragesic, Fentora,

7.

Hydrocodone

Anexsia, Hysingla ER, Lortab, Norco, Reprexain, Vicodin

8.

Hydromorphone

Dilaudid, Dilaudid-HP, Exalgo

9.

Meperidine

Demerol

10. Methadone

Dolophine

11. Morphine

Astramorph PF, Duramorph PF, Embeda, Infumorph,
Kadian

12. Nalbuphine

Nubain

13. Oxycodone

Oxaydo, Oxycet, Oxycontin, Percocet, Percodan, Roxicet

14. Oxymorphone

Opana, Opana ER

15. Pentazocine

Talwin

16. Remifentanil

Ultiva

17. Sufentanil

Sufenta

18. Tapentadol

Nucynta, Nucynta ER

19. Tramadol

Conzip, Ultracet, Ultram, Ultram ER
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Appendix B: Dental Disease Categories, Dental Related ICD-9 and ICD-10 Diagnosis Codes
Dental
Disease
Category
1

Diagnosis

ICD-9 Code

ICD-10 Code

V722

Z01.20

V722

Z01.21

V53.40,V58.50

Z46.4

Supernumerary teeth

520.1

K00.1

Abnormalities of size and form of teeth

520.2

K00.2

Mottled teeth

520.3

K00.3

Disturbances in tooth formation

520.4

K00.4

Hereditary disturbances in tooth structure

520.5

K00.5

Disturbances in tooth eruption

520.6

K00.6

Teething syndrome

520.7

K00.7

Other disorders of tooth development

520.8

K00.8

Disorder of tooth development, unspecified

520.9

K00.9

Embedded teeth

520.6

K01.0

Embedded teeth

520.6

K01.1

Dental caries on smooth surface limited to enamel

521.01, 521.02

K02.61

Dental caries on smooth surface penetrating into
dentin

521.02, 521.07

K02.62

Dental caries on the smooth surface penetrating into
the pulp

521.03, 521.07

K02.63

Cleaning, preventative and fitting procedures
Encounter for dental examination and cleaning without
abnormal findings
Encounter for dental examination and cleaning with
abnormal findings
Encounter for fitting and adjustment of orthodontic
device

2

3

4

Disorders of tooth development

Embedded and Impacted tooth

Dental Caries

71

5

Abrasion and attrition of the teeth
Excessive attrition of teeth

521.10, 521.11,
521.12, 521.13,
521.14, 521.15

K03.0

Abrasion of teeth

521.20, 521.21,
521.22, 521.23,
521.24, 521.25

K03.1

Erosion of the teeth

521.30, 521.31,
521.32, 521.33,
521.34, 521.35

K03.2

Pathological resorption of teeth

521.40, 521.41,
521.42, 521.49

K03.3

523.60

K03.6

Necrosis of the pulp

522.10

K04.1

Pulp degeneration

522.20

K04.2

Abnormal hard tissue formation in pulp

522.30

K04.3

Acute apical periodontitis of pulpal origin

522.40

K04.4

Periapical abscess without sinus

522.50

K04.7

Periodontosis

523.50

K05.4

Other periodontal diseases

523.80

K05.5

Gingival enlargement

523.80

K06.1

Gingival and edentulous alveolar ridge lesions
associated with trauma

523.80

K06.2

Partial loss of teeth due to trauma, unspecified class

525.11

K08.419

Partial loss of teeth due to periodontal diseases,
unspecified class
Partial loss of teeth due to caries, unspecified class

525.12

K08.429

525.13

K08.439

873.63, 873.73

S02.5

Deposits [accretions] on teeth
6

7

8

Disease of the pulp

Gum, periodontal and gingival diseases

Extraction and loss of tooth

Loss of tooth due to fracture

72

9

Developmental cysts of the oral region
Developmental (nonodontogenic) cysts of oral region

10

526.10

K09.1

Perforation of root canal space due to endodontic
treatment

526.61

M27.51

Endodontic overfill

526.62

M27.52

Root canal and endodontic treatment

73
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